The OTSC® Proctology clip system for anal fistula closure: first prospective clinical data.

INTRODUCTION: Anorectal fistulas represent a troublesome condition for both patient and surgeon. The OTSC® Proctology clip system is a new device for transanal anorectal fistula closure. MATERIAL AND METHODS: The OTSC® Proctology system was evaluated in a prospective clinical study undertaken in two surgical proctological centers. Ten patients (three women, seven men; median age 55 years, range 25-73 years) with nine transsphincteric and one suprasphincteric fistulas were enrolled into the study. RESULTS: The median operation time was 30 minutes (range 20-45 minutes). There were no intraoperative technical or surgical complications. Postoperatively, no patient reported intolerable discomfort, immoderate pain or foreign body sensation in the anal region. At follow-up examination six months after surgery, nine out of ten patients had no clinical signs or symptoms of their previous fistula and were considered as healed (success rate 90%). In one patient persistency of the fistula was noted due to spontaneous early clip detachment on the third postoperative day. DISCUSSION: These first data demonstrate the efficacy of the OTSC® Proctology system in the treatment of anal fistulas. Currently, more patients were enrolled into this prospective study to allow further evaluation of this new device and to assess its future role in relation to established surgical strategies for anorectal fistulas.

Efficacy and safety of sclerotherapy with polidocanol foam in comparison with fluid sclerosant in the treatment of first-grade haemorrhoidal disease: a randomised, controlled, single-blind, multicentre trial.

PURPOSE: Sclerotherapy is the treatment of choice for first-grade haemorrhoidal disease. Numerous studies have shown that sclerotherapy with foamed sclerosants is more efficacious than liquid in the treatment of varicose veins. The aim of this study was to assess the efficacy and safety of polidocanol foam in comparison with liquid for haemorrhoidal disease. METHODS: A total of 130 patients were randomised to foam or liquid sclerotherapy (polidocanol 3%). Patients with first-grade haemorrhoidal disease were included and blinded to treatment assignment. The primary endpoint was the stopping of perianal bleeding after one sclerotherapy session. Sclerotherapy was repeated until patients were free of bleeding (2-week intervals). The final follow-up was 12 weeks after the last sclerotherapy session. RESULTS: In the foam group, significantly more patients (88%) were treated successfully after one sclerotherapy session compared to the liquid group (69%; p = 0.01). There was high patient satisfaction in both groups, but significantly more patients were satisfied with their treatment in the foam group than in the liquid group (99 vs. 84%; p = 0.009). Additionally, in the foam group, significantly less treatment sessions were required (p < 0.001), and the total amount of injected polidocanol was reduced (p < 0.001). CONCLUSION: In the therapy of first-grade haemorrhoidal disease, polidocanol 3 % foam is more effective and equally safe compared to liquid polidocanol. The results of this trial show that foam sclerotherapy is a new, innovative, effective and safe non-surgical treatment option for haemorrhoidal disease.